Literature DB >> 32566597

Erratum to efficacy and safety of mecapegfilgrastim for prophylaxis of chemotherapy-induced neutropenia in patients with breast cancer: a randomized, multicenter, active-controlled phase III trial.

Fengrui Xu1,2, Yang Zhang3, Zhanhui Miao4, Xiaohua Zeng5, Biao Wu6, Li Cai7, Jinping Liu8, Shusen Wang9, Xichun Hu10, Wenbo Zheng11, Zhiyue Chen12, Qing Yang12, Zefei Jiang1.   

Abstract

[This corrects the article DOI: 10.21037/atm.2019.07.95.]. 2020 Annals of Translational Medicine. All rights reserved.

Entities:  

Year:  2020        PMID： 32566597      PMCID： PMC7290653          DOI： 10.21037/atm-2020-23

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


Efficacy and safety of mecapegfilgrastim for prophylaxis of chemotherapy-induced neutropenia in patients with breast cancer: a randomized, multicenter, active-controlled phase III trial In the article entitled “Efficacy and safety of mecapegfilgrastim for prophylaxis of chemotherapy-induced neutropenia in patients with breast cancer: a randomized, multicenter, active-controlled phase III trial” (1), the affiliation of Fengrui Xu should be corrected as follows: 1Department of Breast Oncology, Academy of Military Medical Sciences, Beijing 100089, China; 2Department of Breast Oncology, The Fifth Medical Center of Chinese PLA General Hospital, Beijing 100071, China We regret the errors.
  1 in total

1.  Efficacy and safety of mecapegfilgrastim for prophylaxis of chemotherapy-induced neutropenia in patients with breast cancer: a randomized, multicenter, active-controlled phase III trial.

Authors:  Fengrui Xu; Yang Zhang; Zhanhui Miao; Xiaohua Zeng; Biao Wu; Li Cai; Jinping Liu; Shusen Wang; Xichun Hu; Wenbo Zheng; Zhiyue Chen; Qing Yang; Zefei Jiang
Journal:  Ann Transl Med       Date:  2019-09
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.